You are here:
Pharmaceutical Manufacturing — CDMO & OTC
Last Updated:February 27, 2026
About This Investor
JP-B-402
Mandate summary: From Japan, this investor is open to qualified opportunities. Their focus is: Pharmaceutical formulations (CMO/CDMO), generic formulation development and manufacturing, new drug development and manufacturing, contract manufacturing of new drugs, long – listed products, and large – scale OTC drugs Oral solid dosage forms Injectables. The stated objective is Overseas expansion of existing…
Pharmaceutical Manufacturing (CDMO)
Indonesia, Vietnam
Strategic Expansion
$6.54M - $13.1M
Majority / 100%
Request Full Investor Profile
Similar Investors
JP-B-688
Based in Japan, this investor is building pipeline coverage and
Apparel / Fashion
Worldwide
Expanding business areas
$3.27M - $32.7M
Minority/Majority/100%
JP-B-376
Key target profile: Companies dealing in iron – related materials,
Metals / Steel
Bangladesh, India, Vietnam
Acquisition Strategy
$6.54M - $32.7M
Minority preferred / Majority possible
JP-B-285
Based in Japan, this investor is building pipeline coverage and
Packaging
Thailand
Strategic Synergy
Up to $6.54M
Majority / 100%